Pituitary Diseases and Bone

Endocrinology and Metabolism Clinics of North America

Volumn 44, Issue 1, 2015, Pages 171-180

  Mazziotti, Gherardo ^a   Chiavistelli, Silvia ^a   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Bone mineral density; Cortisol; Fractures; Growth hormone; Osteoporosis; Pituitary diseases; Prolactin; Sex steroids

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; PROLACTIN; PROLACTIN RECEPTOR;

ACROMEGALY; ACTH SECRETING ADENOMA; ADRENAL DISEASE; BONE DENSITY; BONE DISEASE; BONE FRAGILITY; BONE REMODELING; BONE TURNOVER; CUSHING DISEASE; FRAGILITY FRACTURE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE SECRETING ADENOMA; HORMONE SUBSTITUTION; HUMAN; HYPOADRENALISM; HYPOPHYSIS DISEASE; HYPOPITUITARISM; HYPOTHYROIDISM; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; SPINE FRACTURE; SPINE RADIOGRAPHY; BONE DISEASES; COMPLICATION; FRACTURES, BONE; METABOLISM;

BONE DISEASES; FRACTURES, BONE; HUMANS; PITUITARY DISEASES;

EID: 84940649964     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2014.10.014     Document Type: Review

References (50)

1. Mazziotti G., Bilezikian J., Canalis E., et al. New understanding and treatments for osteoporosis. Endocrine 2012, 41:58-69.
2. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008, 29:535-559.
3. Iqbal J., Blair H.C., Zallone A., et al. Further evidence that FSH causes bone loss independently of low estrogen. Endocrine 2012, 412:171-175.
4. Omodei U., Mazziotti G., Donarini G., et al. Effects of recombinant follicle-stimulating hormone on bone turnover markers in infertile women undergoing in vitro fertilization procedure. J Clin Endocrinol Metab 2013, 981:330-336.
5. Seriwatanachai D., Krishnamra N., van Leeuwen J.P. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 2009, 107:677-685.
6. Mancini T., Doga M., Mazziotti G., et al. Cushing's syndrome and bone. Pituitary 2004, 7:249-252.
7. Mazziotti G., Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 2013, 95:265-276.
8. Giustina A., Wehrenberg W.B. Influence of thyroid hormones on the regulation of growth hormone secretion. Eur J Endocrinol 1995, 133:646-653.
9. Mazziotti G., Sorvillo F., Piscopo M., et al. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 2005, 20:480-486.
10. Mazziotti G., Porcelli T., Patelli I., et al. Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 2010, 46:747-751.
11. Di Somma C., Colao A., Di Sarno A., et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998, 83:807-813.
12. Naliato E.C., Violante A.H., Caldas D., et al. Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 2008, 11(1):21-28.
13. Colao A., Di Somma C., Loche S., et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol 2000, 52:319-327.
14. Klibanski A., Biller B.M., Rosenthal D.I., et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988, 67:124-130.
15. Vestergaard P., Jørgensen J.O., Hagen C., et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas-a case-control study. Clin Endocrinol (Oxf) 2002, 56(2):159-167.
16. Mazziotti G., Porcelli T., Mormando M., et al. Vertebral fractures in males with prolactinoma. Endocrine 2011, 39:288-293.
17. Mazziotti G., Mancini T., Mormando M., et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 2011, 14(4):299-306.
18. Griffith J.F., Genant H.K. New advances in imaging osteoporosis and its complications. Endocrine 2012, 42:39-51.
19. Klibanski A., Greenspan S.L. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986, 315:542-546.
20. Bonadonna S., Mazziotti G., Nuzzo M., et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005, 20:1837-1844.
21. Mazziotti G., Bianchi A., Bonadonna S., et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 2008, 93:4649-4655.
22. Battista C., Chiodini I., Muscarella S., et al. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin Endocrinol 2009, 70:378-382.
23. Wassenaar M.J., Biermasz N.R., Hamdy N.A., et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 2011, 164:475-483.
24. Padova G., Borzì G., Incorvaia L., et al. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab 2011, 8:37-43.
25. Madeira M., Neto L.V., Torres C.H., et al. Vertebral fracture assessment in acromegaly. J Clin Densitom 2013, 16:238-243.
26. Brzana J., Yedinak C.G., Hameed N., et al. FRAX score in acromegaly: does it tell the whole story?. Clin Endocrinol 2014, 80:614-616.
27. Mazziotti G., Bianchi A., Porcelli T., et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 2013, 98:3402-3410.
28. Claessen K.M., Kroon H.M., Pereira A.M., et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 2013, 98:4808-4815.
29. Giustina A., Casanueva F.F., Cavagnini F., et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003, 26:1242-1247.
30. Melmed S., Casanueva F.F., Klibanski A., et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013, 16:294-302.
31. Canalis E., Mazziotti G., Giustina A., et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
32. Vestergaard P., Lindholm J., Jørgensen J.O., et al. Increased risk of osteoporotic fractures in patients with Cushing's syndrome. Eur J Endocrinol 2002, 146(1):51-56.
33. Trementino L., Appolloni G., Ceccoli L., et al. Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int 2014, 25(3):913-921.
34. Scillitani A., Mazziotti G., Di Somma C., et al. Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. Osteoporos Int 2014, 25(2):441-446.
35. Randazzo M.E., Grossrubatscher E., Dalino Ciaramella P., et al. Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 2012, 15:193-201.
36. Mancini T., Porcelli T., Giustina A. Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag 2010, 6:505-516.
37. Di Somma C., Colao A., Pivonello R., et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf) 1998, 48:655-662.
38. Doga M., Bonadonna S., Gola M., et al. Growth hormone deficiency in the adult. Pituitary 2006, 9:305-311.
39. Doga M., Bonadonna S., Gola M., et al. GH deficiency in the adult and bone. J Endocrinol Invest 2005, 28(8 Suppl):18-23.
40. Högler W., Shaw N. Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol (Oxf) 2010, 72(3):281-289.
41. Murray R.D., Adams J.E., Shalet S.M. A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J Clin Endocrinol Metab 2006, 91(2):432-438.
42. Wuster C., Abs R., Bengtsson B.A., et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001, 16:398-405.
43. Rosen T., Wilhelmsen L., Landin-Wilhelmsen K., et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997, 137:240-245.
44. Mazziotti G., Bianchi A., Bonadonna S., et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 2006, 21(4):520-528.
45. Mazziotti G., Bianchi A., Cimino V., et al. Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary 2008, 11:55-61.
46. Ohlsson C., Bengtsson B.A., Isaksson O.G., et al. Growth hormone and bone. Endocr Rev 1998, 19(1):55-79.
47. Barake M., Klibanski A., Tritos N.A. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 2014, 99(3):852-860.
48. Hazem A., Elamin M.B., Bancos I., et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol 2012, 166:13-20.
49. Mazziotti G., Mormando M., Cristiano A., et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol 2014, 170(6):893-899.
50. Mazziotti G., Porcelli T., Bianchi A., et al. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 2010, 163:15-20.